Research Progress of Risk Factors of Atherosclerosis in Patients with Chronic Kidney Disease

Home > Archive>Volume 24, Issue 1, 2016 >101-104

Research Progress of Risk Factors of Atherosclerosis in Patients with Chronic Kidney Disease
DOI:
                        
                    
CSTR:
                        
                    
Author:
                        TANG Bing-YaoTANG Bing-Yao
Department of Nephrology, the Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050001, China
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site
LI Shao-MeiLI Shao-Mei
Department of Nephrology, the Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050001, China
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site

                    
Affiliation:Department of Nephrology, the Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050001, China)
Clc Number:R5
Fund Project:

Article

Figures

Metrics

Reference [37]

Cited by

Materials

Comments

Abstract:

Cardiovascular disease is the most common complication of chronic kidney disease, and atherosclerosis is the main cause of cardiovascular disease. Controlling the degree of atherosclerosis and its related risk factors can relieve the chronic kidney disease patients' illness, reduce the mortality, and it has important significance in clinic.

Key words:Chronic Kidney Disease; Atherosclerosis; Risk Factors

Reference

[1] Lai S, Dimko M, Galani A, et al.Early markers of cardiovascular risk in chronic kidney disease.Ren Fail, 5,7(2):254-261.

[2] Manjunath G, Tighiouart H, Ibrahim H, et al.Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community.J Am Coll Cardiol, 3,1(1):47-55.

[3] Bao YS, Jia XB, Ji Y, et al.High prevalence and risk factors for kidney dysfunction in patients with atherosclerotic cardio-cerebrovascular disease.QJM, 4,7(6):443-449.

[4] Rivara MB, Ravel V, Kalantar-Zadeh K, et al.Uncorrected and albumin-corrected calcium, phosphorus, and mortality in patients undergoing maintenance dialysis.J Am Soc Nephrol, 5,6(7):1 671-681.

[5] Setiani-Agus L, Effendi I, Abdillah S.Influence of the use of phosphate binders on serum levels of calcium phosphate in patients with chronic kidney disease undergoing hemodialysis:A retrospective and prospective study.Saudi Pharm J, 4,2(4):333-337.

[6] McGovern AP, de Lusignan S, van Vlymen J, et al.Serum phosphate as a risk factor for cardiovascular events in people with and without chronic kidney disease:a large community based cohort study.PLoS One, 3,8(9):1-9.

[7] Hirata Y, Yamamoto E, Tokitsu T, et al.Reactive oxidative metabolites are associated with the severity of heart failure and predict future cardiovascular events in heart failure with preserved left ventricular ejection fraction.Int J Cardiol, 5,0(179):305-308.

[8] Sureshbabu A, Ryter SW, Choi ME.Oxidative stress and autophagy:Crucial modulators of kidney injury.Redox Biol, 5,4:208-214.

[9] Verma AK, Chandra S, Singh RG, et al.Serum prolidase activity and oxidative stress in diabetic nephropathy and end stage renal disease:a correlative study with glucose and creatinine.Biochen Res Int, 4,4:1-7.

[10] Turkmen K, Tonbul HZ, Erdur FM, et al.Peri-aortic fat tissue and malnutrition-inflammation-atherosclerosis/calcification syndrome in end-stage renal disease patients.Int Urol Nephrol, 3,5(3):857-867.

[11] Yamada S, Tokumoto M, Tatsumoto N, et al.Phosphate overload directly induces systemic inflammation and malnutrition as well as vascular calcification in uremia.Am J Physiol Renal Physiol, 4,6(12):1 418-428.

[12] Gitsioudis G, Schüssler A, Nagy E, et al.Combined assessment of high-sensitivity troponin T and noninvasive coronary plaque composition for the prediction of cardiac outcomes.Radiology, 5,6(1):73-81.

[13] Assa S, Hummel YM, Voors AA, et al.Hemodialysis-induced regional left ventricular systolic dysfunction and inflammation:a cross-sectional study.Am J Kidney Dis, 4,4(2):265-273.

[14] Wakuda H, Uchida S, Ikeda M, et al.Is hyperuricemia a risk factor for arteriosclerosis? Uric acid and arteriosclerosis in apolipoprotein E-deficient mice.Biol Pharm Bull, 4,7(12):1 866-871.

[15] Chen Y, Xu B, Sun W et al.Impact of the serum uric acid level on subclinical atherosclerosis in middle-aged and elderly Chinese.J Atheroscler Thromb, 5,7(1):1-10.

[16] Lobo JC, Stockler-Pinto MB, da Nóbrega AC, et al.Is there association between uric acid and inflammation in hemodialysis patients?.Ren Fail, 3,5(3):361-366.

[17] 杜美容, 李元健, 江俊麟.ADMA与糖尿病血管并发症的研究进展.中国动脉硬化杂志, 5,3(8):845-850.

[18] Antoniades C, Demosthenous M, Tousoulis D, et al.Role of asymmetrical dimethylarginine in inflammation-induced endothelial dysfunction in human atherosclerosis.Hypertension, 1,8(1):93-98.

[19] Alpoim PN, Sousa LP, Mota AP, et al.Asymmetric dimethylarginine (ADMA) in cardiovascular and renal disease.Clin Chim Acta, 5,2(440):36-39.

[20] Ravani P, Tripepi G, Malberti F, et al.Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease:a competing risks modeling approach.J Am Soc Nephrol, 5,6(8):2 449-455.

[21] McCully KS.Homocysteine and the pathogenesis of atherosclerosis.Expert Rev Clin Pharmacol, 5,8(2):211-219.

[22] Tbahriti HF, Messaoudi A, Kaddous A, et al.The degree of chronic renal failure is associated with the rate of pro-inflammatory cytokines, hyperhomocysteinemia and with oxidative stress.Ann Cardiol Angeiol (Paris), 4,3(3):135-139.

[23] Wu CC, Zheng CM, Lin YF, et al.Role of homocysteine in end-stage renal disease.Clin Biochem, 2,5(16):1 286-294.

[24] Pawlak K, Mysliwiec M, Pawlak D.Hyperhomocysteinemia and the presence of cardiovascular disease are associated with kynurenic acid levels and carotid atherosclerosis in patients undergoing continuous ambulatory peritoneal dialysis.Thromb Red, 2,9(6):704-709.

[25] Aydin FN, Agilli M, Cayci T, et al.The effect of serum fetuin-A on atherosclerosis in hemodialysis patients.Saudi J Kidney Dis Transpl, 5,6(2):370-372.

[26] Chen HY, Chiu YL, Hsu SP, et al.Fetuin A nutritional status predicts cardiovascular outcomes and survival in hemodialysis patients.Am J Nephrol, 4,0(3):233-241.

[27] Liu SW, Qiao SB, Yuan JS, et al.Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans.Clin Endocrinol (Oxf), 9,1(2):202-207.

[28] Tang X, Chen M, Zhang W.Association between elevated visfatin and carotid atherosclerosis in patients with chronic kidney disease.Zhong Nan Da Xue Xue Bao Yi Xue Ban, 3,8(6):553-559.

[29] Lu YC, Hsu CC, Yu TH, et al.Association between visfatin levels and coronary artery disease in patients with chronic kidney disease.Iran J Kidney Dis, 3,7(6):446-452.

[30] Mu J, Feng B, Ye Z, et al.Visfatin is related to lipid dysregulation, endothelial dysfunction and atherosclerosis in patients with chronic kidney disease.J Nephrol, 1,4(2):177-184.

[31] Esteghamati A, Sheikhbahaei S, Hafezi-Nejad N, et al.Serum osteoprotegerin in relation to metabolic status, severity, and estimated risk of subsequent coronary heart disease.Arch Iran Med, 4,7(9):596-601.

[32] Dzgoeva FU, Gatagonova TM, Bestaeva TL, et al.Osteoprotegerin and fibroblast growth factor 23 in the development of cardiovascular events inchronic kidney disease.Ter Arkh, 4,6(6):63-69.

[33] Scialla JJ, Kao WH, Crainiceanu C, et al.Biomarkers of vascular calcification and mortality in patients with ESRD.Ciln J Am Soc Nephrol, 4,9(4):745-755.

[34] Nascimento MM, Hayashi SY.Elevated levels of plasma osteoprotegerin are associated with all-cause mortality risk and atherosclerosis in patients with stages 3 to 5 chronic kidney disease.Braz J Med Biol Res, 4,7(11):995-1002.

[35] Mordi I, Tzemos N.Is reversal of endothelial dysfunction still an attractive target in modern cardiology?.World J Cardiol, 4,6(8):824-835.

[36] Moallem SA, Nazemian F, Eliasi S, et al.Correlation between cathepsin D serum concentration and carotid intima-media thickness in hemodialysis patients.Int Urol Nephrol, 1,3(3):841-848.

[37] Ozkayar N, Piskinpasa S, Akyel F, et al.Relation between serum cathepsin D levels and endothelial dysfunction in patients with chronic kidney disease.Nefrologia, 5,5(1):72-79.

Get Citation

TANG Bing-Yao, LI Shao-Mei. Research Progress of Risk Factors of Atherosclerosis in Patients with Chronic Kidney Disease[J]. Editorial Office of Chinese Journal of Arteriosclerosis,2016,24(1):101-104.

Copy

Article Metrics

Abstract:851
PDF: 662
HTML: 0
Cited by: 0

History

Received:April 23,2015
Revised:September 21,2015
Adopted:
Online: November 19,2018
Published:

Policies & Instructions

Get Citation

Share

Article Metrics

History

Article QR Code